Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03682913
Other study ID # 0105-18-HMO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2018
Est. completion date August 30, 2019

Study information

Verified date September 2018
Source Hebrew University of Jerusalem
Contact Shahaf Leshem, B.A.
Phone 0545455509
Email shahaf.leshem@mail.huji.ac.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obsessive-compulsive disorder (OCD) is a severe mental illness characterized by repetitive behaviors that a person feels compelled to perform. It has been demonstrated that stimuli in the environment can trigger the compulsive urge, perpetuating the OCD cycle. The main goal of the current proposal, which is based on exciting pilot data, is to test a novel computerized training program to create an association between OCD-related stimuli, which typically trigger the compulsive urge, and the brain system responsible for stopping. The idea is that once this system is triggered, it will be easier for patients to stop the compulsive urge.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 30, 2019
Est. primary completion date July 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- OCD patients

Exclusion Criteria:

- Metal/ electronic device

- Under the age of 18

- Pregnant women

- Tattoos that cover over 10% of body mass

- Chronically ill patients

- Psychosis/ Bi-polar

- Substance abuse

- Sever depression

- Active suicide thoughts

- Hearing loss

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
P-CIT protocol
Personalized inhibitory control training for one week.
Placebo
without personalized inhibitory control training for one week.

Locations

Country Name City State
Israel The Hebrew University of Jerusalem Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
Hebrew University of Jerusalem

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary fMRI- changed inhibition levels in the pre-SMA area in experimental group in comparison to control group During tasks that require inhibition One week after P-CIT training starts
Primary fMRI- changed inhibition levels in the rIFG area in experimental group in comparison to control group During tasks that require inhibition One week after P-CIT training starts
Secondary Behavioural- Y-bocs (Yale-Brown Obsessive-Compulsive Scale) score- change in OCD symptoms in experimental group in comparison to placebo group Clinical assessment. Semi-structured interview that assesses the presence and severity of obsessions and compulsions over the past week. The 5-item Obsession Severity and Compulsion Severity subscales are summed to produce a Total Severity score. Symptoms endorsed are rated on a scale from none (0) to extreme (5). The 5-item Obsession Severity and Compulsion Severity subscales are summed to produce a Total Severity score. One week after P-CIT (Personalized Inhibitory Control Training for Compulsive Behavior Change) training
Secondary Behavioural- M.I.N.I (Mini-International Neuropsychiatric Interview) score- change in OCD symptoms in experimental group in comparison to placebo group Clinical assessment. Structural interview. One week after P-CIT (Personalized Inhibitory Control Training for Compulsive Behavior Change) training
Secondary Behavioural- OCI-R (Obsessive-Compulsive Inventory) score- change in OCD symptoms in experimental group in comparison to placebo group Clinical assessment. Cutoff score of 21 is distinguish individuals with OCD from those without anxiety disorders. One week after P-CIT (Personalized Inhibitory Control Training for Compulsive Behavior Change) training
See also
  Status Clinical Trial Phase
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00215137 - Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder Phase 2
Recruiting NCT06050369 - Objective Characterizatoion of Repetitive Behaviors N/A
Recruiting NCT06347978 - Personalized DBS for OCD Guided by Stereoencephalography Mapping N/A
Withdrawn NCT03926546 - Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT05712057 - Neurostimulation Versus Therapy for Problems With Emotions N/A
Not yet recruiting NCT03313622 - Locating Biomarkers in OCD Through Behavioral Tasks
Withdrawn NCT03842345 - DELPhI Evaluation of Psychiatric Conditions
Completed NCT02866422 - Development of an Instrument That Monitors Behaviors Associated With OCD N/A
Completed NCT01833442 - Randomized Controlled Meditation Trial for Treating OCD N/A
Recruiting NCT04904952 - Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients N/A
Completed NCT05981690 - Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT02500888 - Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder N/A
Recruiting NCT06244121 - Effect of Pyridoxine as Add-on Therapy in OCD Patients N/A
Recruiting NCT05580614 - Paired tVNS With ERP in OCD N/A
Active, not recruiting NCT03511534 - Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder N/A
Recruiting NCT05624528 - A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder Phase 2
Recruiting NCT05881356 - Discovering Factors in the Clinical Study Journey of Patients With OCD
Recruiting NCT05359562 - How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD N/A
Recruiting NCT03459456 - Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)